Scarica l'app Stockscreener
0.2453
9.52%
-0.0258
Dopo l'orario di chiusura:
.26
0.0147
+5.99%
Precedente Chiudi:
$0.2711
Aprire:
$0.2635
Volume 24 ore:
1.87M
Relative Volume:
1.05
Capitalizzazione di mercato:
$2.91M
Reddito:
-
Utile/perdita netta:
$-22.71M
Rapporto P/E:
-0.0209
EPS:
-11.71
Flusso di cassa netto:
$-18.24M
1 W Prestazione:
-33.56%
1M Prestazione:
-34.93%
6M Prestazione:
-32.18%
1 anno Prestazione:
-91.77%
Intervallo 1D:
$0.23
$0.2635
Intervallo di 1 settimana:
$0.23
$0.405
Portata 52W:
$0.23
$4.0899
Genprex Inc Stock (GNPX) Company Profile
Nome
Genprex Inc
Settore
Industria
Telefono
512-537-7997
Indirizzo
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Confronta GNPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.2453 | 2.91M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-26 | Iniziato | National Securities | Buy |
| 2019-04-29 | Iniziato | Noble Capital Markets | Outperform |
Genprex Inc Borsa (GNPX) Ultime notizie
Genprex (GNPX) Projected to Announce Earnings on Monday - Defense World
Genprex stock plunges to 52-week low of $0.27 - Investing.com
Genprex reports progress in lung cancer gene therapy By Investing.com - Investing.com South Africa
Genprex reports progress in lung cancer gene therapy - Investing.com India
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Quantisnow
Game-Changing Gene Therapy Could End Daily Insulin Injections for Diabetes Patients - Stock Titan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® De - GuruFocus.com
Genprex Inc (GNPX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Genprex to Participate at BIO Europe Spring 2025 - StreetInsider.com
Can Genprex's Presence at BIO Europe Spring Attract New Partnership Opportunities? - Stock Titan
Genprex to Present at the 2020 LD Micro Virtual Conference - ACCESS Newswire
Genprex Strengthens Diabetes Focus with New License - TipRanks
Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria
Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com
Genprex explores non-viral gene therapy for diabetes - Investing.com India
Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough - StockTitan
Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria
Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com
Genprex announces advancement of its diabetes gene therapy program - TipRanks
Genprex advances diabetes gene therapy with new license - Investing.com India
Genprex Provides Update on Diabetes Gene Therapy Program - Nasdaq
Genprex faces Nasdaq delisting over stock price, equity issues - MSN
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - BioSpace
Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq
Understanding GNPX’s financial ratios: A beginner’s guide - US Post News
Major Cancer Treatment Breakthrough: New Gene Therapy Defeats Drug-Resistant Lung Cancer - Stock Titan
Genprex faces Nasdaq delisting over stock price, equity issues By Investing.com - Investing.com Canada
Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register
Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire
Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World
Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SEC Form 424B5 filed by Genprex Inc. - Quantisnow
Genprex Completes Phase 1 Dose Escalation of Acclaim-3 Clinical Trial for ES-SCLC PatientsGenprex, Inc. (NASDAQ:GNPX) announced in a press release dated December 16, 2024, the successful completion of the Phase 1 dose escalation segment of the - Defense World
Genprex advances to phase 2 in lung cancer trial - Investing.com
Genprex's Reqorsa Advances to Phase 2 After Successful Safety Trial in Lung Cancer Treatment - StockTitan
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PR Newswire
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - The Eastern Progress Online
Genprex to Participate in 2024 BIO Europe Conference - The Eastern Progress Online
Genprex Inc Azioni (GNPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):